Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.52 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.52 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL649503 | 0.85 | CHRNB2 (0.47) | CHRNB2CHRNA4HCRTR1HCRTR2CHRNB4 | |
| SCHEMBL649502 | 0.85 | CHRNB2 (0.47) | CHRNB2CHRNA4HCRTR1HCRTR2CHRNB4 | |
| SCHEMBL651044 | 0.80 | CHRNB2 (0.79) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL651042 | 0.80 | CHRNB2 (0.79) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1843239 | 0.76 | CYP2C9 (0.52) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL651095 | 0.76 | CHRNB2 (0.58) | CHRNB2CHRNA4HCRTR1HCRTR2CHRNB4 | |
| SCHEMBL651096 | 0.76 | CHRNB2 (0.58) | CHRNB2CHRNA4HCRTR1HCRTR2CHRNB4 | |
| SCHEMBL2064797 | 0.74 | CHRNB2 (0.40) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL11028141 | 0.74 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL23701407 | 0.73 | MAPT (0.48) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | CHRNB2 11/4885CHRNA4 8/4885HCRTR1 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.